Arnon P. Kater

12.9k total citations · 3 hit papers
225 papers, 5.5k citations indexed

About

Arnon P. Kater is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Arnon P. Kater has authored 225 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Genetics, 88 papers in Pathology and Forensic Medicine and 73 papers in Immunology. Recurrent topics in Arnon P. Kater's work include Chronic Lymphocytic Leukemia Research (198 papers), Lymphoma Diagnosis and Treatment (87 papers) and Immunodeficiency and Autoimmune Disorders (42 papers). Arnon P. Kater is often cited by papers focused on Chronic Lymphocytic Leukemia Research (198 papers), Lymphoma Diagnosis and Treatment (87 papers) and Immunodeficiency and Autoimmune Disorders (42 papers). Arnon P. Kater collaborates with scholars based in Netherlands, United States and Germany. Arnon P. Kater's co-authors include Eric Eldering, Marinus H. J. van Oers, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, Sanne H. Tonino, Tadeusz Robak, John F. Seymour, Paolo Ghia and Mehrdad Mobasher and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Arnon P. Kater

220 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 595 citations John F. Seymour, Thomas J. Kipps et al. profile →
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 339 citations Barbara Eichhorst, Tadeusz Robak et al. profile →
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

2025 21 citations Jennifer R. Brown, John F. Seymour et al. profile →

Peers

Countries citing papers authored by Arnon P. Kater

Since Specialization

Citations

This map shows the geographic impact of Arnon P. Kater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnon P. Kater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnon P. Kater more than expected).

Fields of papers citing papers by Arnon P. Kater

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnon P. Kater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnon P. Kater. The network helps show where Arnon P. Kater may publish in the future.

Co-authorship network of co-authors of Arnon P. Kater

This figure shows the co-authorship network connecting the top 25 collaborators of Arnon P. Kater. A scholar is included among the top collaborators of Arnon P. Kater based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnon P. Kater. Arnon P. Kater is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia 2025 ·Cellular and Molecular Immunology ·(unknown), (unknown), (unknown), Gaspard Cretenet, (unknown), Bauke V. Schomakers, Michel van Weeghel, (unknown), Sanne G. S. Verberk, Jan Van den Bossche, Mirjam Langeveld, Fleur S. Kleijwegt, Eric Eldering, Noam Zelcer, Arnon P. Kater, Helga Simon‐Molas	4
2	SINGLE-AGENT EPCORITAMAB LEADS TO DEEP RESPONSES IN PATIENTS (PTS) WITH RICHTER’S TRANSFORMATION (RT): PRIMARY RESULTS FROM THE EPCORE CLL-1 TRIAL 2024 ·University of Southern Denmark Research Portal (University of Southern Denmark) ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, (unknown), Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, (unknown), А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, (unknown)	1
3	Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care 2024 ·Cancers ·Mary Ann Anderson, Renata Walewska, (unknown), Arnon P. Kater, Josie Montegaard, Susan O’Brien, John F. Seymour, Matthew D. Smith, Stephan Stilgenbauer, (unknown), Jennifer R. Brown	2
4	Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab 2024 ·HemaSphere ·Arnon P. Kater, Barbara Eichhorst, Carolyn Owen, Ulrich Jaeger, Brenda Chyla, Marcus Lefebure, Rosemary Millen, Yanwen Jiang, Maria Thadani‐Mulero, Michelle Boyer, John F. Seymour	1
5	Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Arnon P. Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose Sandoval‐Sus, Mazyar Shadman, Christian Bjørn Poulsen, Jacob Haaber Christensen, Meghan C. Thompson, (unknown), А. А. Кузнецова, Toshihiko Oki, Rebecca Valentin, Mar Bellido, (unknown)	2
6	Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials 2024 ·Clinical Cancer Research ·(unknown), Hanne Vibeke Marquart, Hans Jakob Hartling, Jakob Thaning Bay, Caspar da Cunha‐Bang, Christian Brieghel, (unknown), Lisbeth Enggaard, Arnon P. Kater, Mark‐David Levin, Sabina Kersting, Sisse Rye Ostrowski, Carsten Utoft Niemann	1
7	MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) 2023 ·Hematological Oncology ·Arnon P. Kater, Rosemary Harrup, Thomas J. Kipps, Barbara Eichhorst, Carolyn Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani‐Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F. Seymour	8
8	Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors 2023 ·Leukemia ·Anne W. J. Martens, Inga Kavazović, (unknown), (unknown), Ramon Arens, Aldo Jongejan, Perry D. Moerland, Eric Eldering, Gerritje J. W. van der Windt, Felix M. Wensveen, (unknown), Arnon P. Kater	14
9	T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia 2023 ·Blood Advances ·(unknown), (unknown), Gaspard Cretenet, (unknown), Bauke V. Schomakers, Michel van Weeghel, Arnon P. Kater, Helga Simon‐Molas, Eric Eldering	7
10	Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial 2022 ·The Journal of Infectious Diseases ·(unknown), (unknown), Inger S. Nijhof, Abraham Goorhuis, Arnon P. Kater, (unknown), Francis Swaneveld, V.M.J. Novotný, Susanne Bogers, Matthijs R. A. Welkers, Grigorios Papageorgiou, Bart Rijnders, Jarom Heijmans	16
11	Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells 2022 ·Blood Advances ·(unknown), Gerritje J. W. van der Windt, Mels Hoogendoorn, Julie Dubois, Arnon P. Kater, (unknown)	15
12	Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL 2022 ·Cancer Research Communications ·McKensie Collins, In-Young Jung, Ziran Zhao, (unknown), Weimin Kong, Stefan Lundh, Joseph A. Fraietta, Arnon P. Kater, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst	11
13	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas 2022 ·Cancer Research Communications ·Anne W. J. Martens, (unknown), Renate de Boer, (unknown), An Ngo‐Huang, (unknown), Koen de Heer, Marcel Spaargaren, Christie P.M. Verkleij, Niels W.C.J. van de Donk, Homer Adams, Eric Eldering, Carel J.M. van Noesel, Raluca Verona, Arnon P. Kater	9
14	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment 2022 ·Blood ·(unknown), Helga Simon‐Molas, Gaspard Cretenet, Beatriz Valle‐Argos, Lindsay Smith, Francesco Forconi, Bauke V. Schomakers, Michel van Weeghel, (unknown), (unknown), (unknown), Jeffrey C. Rathmell, Gerritje J. W. van der Windt, Arnon P. Kater, Graham Packham, Eric Eldering	27
15	Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing 2021 ·Blood Advances ·Dieke J. van Rees, Maximilian Brinkhaus, (unknown), Paul Verkuijlen, Anton T. J. Tool, Karin Schornagel, Louise W. Treffers, Michel van Houdt, Arnon P. Kater, Gestur Vidarsson, Andrew R. Gennery, Taco W. Kuijpers, Robin van Bruggen, Hanke L. Matlung, Timo K. van den Berg	19
16	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies 2020 ·Cancer Immunology Research ·Iris de Weerdt, Roeland Lameris, George L. Scheffer, (unknown), Renate de Boer, Anita G.M. Stam, Rieneke van de Ven, Mark‐David Levin, Steven T. Pals, Rob C. Roovers, Paul W.H.I. Parren, Tanja D. de Gruijl, Arnon P. Kater, Hans van Vliet	32
17	Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL 2017 ·Blood ·(unknown), (unknown), Stacey M. Fernandes, Constantine S. Tam, Francesco Forconi, Rachel M. Guerra, Gregory H. Bird, Loren D. Walensky, Jennifer R. Brown, Arnon P. Kater, Eric Eldering	3
18	How does lenalidomide target the chronic lymphocytic leukemia microenvironment? 2014 ·Blood ·Arnon P. Kater, Sanne H. Tonino, Alexander Egle, Alan G. Ramsay	46
19	Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia 2011 ·Clinical Cancer Research ·Jacqueline M. Tromp, Christian R. Geest, Esther C.W. Breij, (unknown), (unknown), Dieuwertje M. Luijks, Arnon P. Kater, Tim Beaumont, Marinus H. J. van Oers, Eric Eldering	79
20	In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow 2008 ·Cancer Research ·Rogier van Gent, Arnon P. Kater, Sigrid A. Otto, Annelieke Jaspers, José A. M. Borghans, Nienke Vrisekoop, (unknown), An F.C. Ruiter, Shulamiet Wittebol, Eric Eldering, Marinus H. J. van Oers, Kiki Tesselaar, Marie José Kersten, Frank Miedema	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact